| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2008PNAS..105.8363K |
| P356 | DOI | 10.1073/PNAS.0800371105 |
| P932 | PMC publication ID | 2448842 |
| P698 | PubMed publication ID | 18523022 |
| P5875 | ResearchGate publication ID | 51399395 |
| P50 | author | Chetan Eknath Chitnis | Q5094149 |
| Peter A. Zimmerman | Q39408524 | ||
| Ivo Mueller | Q60043791 | ||
| Pascal Michon | Q114069796 | ||
| P2093 | author name string | Jennifer L Cole-Tobian | |
| Christopher L King | |||
| Ahmad Rushdi Shakri | |||
| Danielle Stanisic | |||
| Alexandra Marcotty | |||
| P2860 | cites work | The Resistance Factor to Plasmodium vivax in Blacks | Q22250916 |
| Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein | Q28471832 | ||
| A family of erythrocyte binding proteins of malaria parasites | Q33198214 | ||
| A challenge for the development of malaria vaccines: polymorphic target antigens | Q33280141 | ||
| The Duffy receptor family of Plasmodium knowlesi is located within the micronemes of invasive malaria merozoites | Q33941679 | ||
| Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion | Q34331219 | ||
| Plasmodium vivax interaction with the human Duffy blood group glycoprotein: identification of a parasite receptor-like protein | Q34510605 | ||
| Reduced Plasmodium vivax erythrocyte infection in PNG Duffy-negative heterozygotes | Q35690828 | ||
| Host age as a determinant of naturally acquired immunity to Plasmodium falciparum | Q35846186 | ||
| The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytes | Q36367429 | ||
| Immune responses to asexual blood-stages of malaria parasites | Q36412872 | ||
| Mapping regions containing binding residues within functional domains of Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins. | Q36707751 | ||
| Diagnosing infection levels of four human malaria parasite species by a polymerase chain reaction/ligase detection reaction fluorescent microsphere-based assay | Q37058435 | ||
| High-throughput identification of the predominant malaria parasite clone in complex blood stage infections using a multi-SNP molecular haplotyping assay. | Q37058446 | ||
| The risk of malarial infections and disease in Papua New Guinean children. | Q37088901 | ||
| Conserved residues in the Plasmodium vivax Duffy-binding protein ligand domain are critical for erythrocyte receptor recognition | Q37595658 | ||
| Development of a real-time PCR assay for detection of Plasmodium falciparum, Plasmodium vivax, and Plasmodium ovale for routine clinical diagnosis | Q40526899 | ||
| Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). | Q45273570 | ||
| Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion | Q45273574 | ||
| Dynamics of asymptomatic Plasmodium vivax infections and Duffy binding protein polymorphisms in relation to parasitemia levels in Papua New Guinean children | Q46913445 | ||
| Analysis of repeated hemoglobin measures in full-term, normal birth weight Kenyan children between birth and four years of age. III. The Asemobo Bay Cohort Project | Q47246954 | ||
| The erythrocyte binding motif of plasmodium vivax duffy binding protein is highly polymorphic and functionally conserved in isolates from Papua New Guinea | Q47876528 | ||
| Malaria vaccines based on the Plasmodium falciparum merozoite surface protein 3--should we avoid amino acid sequence polymorphisms or embrace them? | Q48037107 | ||
| Immune effector mechanisms in malaria | Q82383609 | ||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| Plasmodium vivax | Q311376 | ||
| P304 | page(s) | 8363-8368 | |
| P577 | publication date | 2008-06-03 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infection | |
| P478 | volume | 105 |
| Q98187263 | A Humanized Mouse Model for Plasmodium vivax to Test Interventions that Block Liver Stage to Blood Stage Transition and Blood Stage Infection |
| Q34254934 | A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines |
| Q36225497 | A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivax |
| Q34145333 | Advances and challenges in malaria vaccine development. |
| Q89790993 | Amplification of Duffy binding protein-encoding gene allows Plasmodium vivax to evade host anti-DBP humoral immunity |
| Q47150417 | An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies |
| Q41150428 | An immunomics approach for the analysis of natural antibody responses to Plasmodium vivax infection |
| Q64237708 | Antibody responses to Plasmodium vivax Duffy binding and Erythrocyte binding proteins predict risk of infection and are associated with protection from clinical Malaria |
| Q34726966 | B cell epitope mapping and characterization of naturally acquired antibodies to the Plasmodium vivax Merozoite Surface Protein-3α (PvMSP-3α) in malaria exposed individuals from Brazilian Amazon |
| Q33884976 | Blood groups and malaria: fresh insights into pathogenesis and identification of targets for intervention |
| Q59129806 | Blood-stage Plasmodium vivax antibody dynamics in a low transmission setting: A nine year follow-up study in the Amazon region |
| Q36978206 | Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein |
| Q34256740 | Characterization of inhibitory anti-Duffy binding protein II immunity: approach to Plasmodium vivax vaccine development in Thailand |
| Q35805433 | Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodies |
| Q56359213 | Cytotoxic CD8 T cells recognize and kill Plasmodium vivax-infected reticulocytes |
| Q35666191 | Design and Immunogenicity of a Novel Synthetic Antigen Based on the Ligand Domain of the Plasmodium vivax Duffy Binding Protein |
| Q33918156 | Determination of the molecular basis for a limited dimorphism, N417K, in the Plasmodium vivax Duffy-binding protein |
| Q48019458 | Development of quantitative receptor-ligand binding assay for use as a tool to estimate immune responses against Plasmodium vivax Duffy binding protein Region II. |
| Q38597276 | Development of vaccines for Plasmodium vivax malaria |
| Q33530114 | Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children |
| Q35141958 | Duffy antigen receptor for chemokine (DARC) polymorphisms and its involvement in acquisition of inhibitory anti-duffy binding protein II (DBPII) immunity |
| Q36464343 | Duffy blood group system and the malaria adaptation process in humans |
| Q94606197 | Dynamics of IgM and IgG responses to the next generation of engineered Duffy binding protein II immunogen: Strain-specific and strain-transcending immune responses over a nine-year period |
| Q34078790 | Evaluation of naturally acquired IgG antibodies to a chimeric and non-chimeric recombinant species of Plasmodium vivax reticulocyte binding protein-1: lack of association with HLA-DRB1*/DQB1* in malaria exposed individuals from the Brazilian Amazon. |
| Q34994491 | Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein |
| Q34236565 | Fy(a)/Fy(b) antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria |
| Q38457784 | Genetic diversity and natural selection of Duffy binding protein of Plasmodium vivax Korean isolates |
| Q39217481 | Genetic diversity, haplotypes and allele groups of Duffy binding protein (PkDBPαII) of Plasmodium knowlesi clinical isolates from Peninsular Malaysia |
| Q21558777 | Glycan masking of Plasmodium vivax Duffy Binding Protein for probing protein binding function and vaccine development |
| Q36114619 | Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis |
| Q92797716 | Human antibodies against DBP |
| Q47279598 | Human genetics of infectious diseases: Unique insights into immunological redundancy |
| Q33798074 | Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies. |
| Q92827824 | Identification and Characterization of Functional Human Monoclonal Antibodies to Plasmodium vivax Duffy-Binding Protein |
| Q64054791 | Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain |
| Q41994105 | Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development |
| Q36965601 | Immunogenetic markers associated with a naturally acquired humoral immune response against an N-terminal antigen of Plasmodium vivax merozoite surface protein 1 (PvMSP-1). |
| Q34260750 | Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II. |
| Q38938701 | Immunogenicity of glycosylphosphatidylinositol-anchored micronemal antigen in natural Plasmodium vivax exposure |
| Q39115271 | Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II. |
| Q39252580 | Immunogenicity of the Plasmodium vivax merozoite surface protein 1 paralog in the induction of naturally acquired antibody and memory B cell responses. |
| Q34234390 | Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis |
| Q34658695 | In silico studies on DARC. |
| Q38260972 | Innate sensing of malaria parasites |
| Q38728598 | Insights into the naturally acquired immune response to Plasmodium vivax malaria |
| Q37583147 | Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite |
| Q57299814 | Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial |
| Q33676028 | Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodies |
| Q26772878 | Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria |
| Q37775257 | Multiple interests in structural models of DARC transmembrane protein. |
| Q41071739 | Natural acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein (PvDBP-II) equally block erythrocyte binding of homologous and heterologous expressed PvDBP-II on the surface of COS-7 cells |
| Q46926980 | Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein and Clinical Immunity to Malaria in Rural Amazonians. |
| Q37647647 | Naturally Acquired Binding-Inhibitory Antibodies to Plasmodium vivax Duffy Binding Protein in Pregnant Women Are Associated with Higher Birth Weight in a Multicenter Study |
| Q38853118 | Naturally Acquired Human Antibodies Against Reticulocyte-Binding Domains of Plasmodium vivax Proteins, PvRBP2c and PvRBP1a, Exhibit Binding-Inhibitory Activity |
| Q33617528 | Naturally acquired antibodies to Plasmodium vivax Duffy binding protein (DBP) in Brazilian Amazon |
| Q37308698 | Naturally acquired immune responses to P. vivax merozoite surface protein 3α and merozoite surface protein 9 are associated with reduced risk of P. vivax malaria in young Papua New Guinean children |
| Q47812027 | Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection |
| Q28394065 | Naturally-acquired humoral immune responses against the N- and C-termini of the Plasmodium vivax MSP1 protein in endemic regions of Brazil and Papua New Guinea using a multiplex assay |
| Q55382338 | Persistence of Long-lived Memory B Cells specific to Duffy Binding Protein in individuals exposed to Plasmodium vivax. |
| Q35673121 | Plasmodium simium, a Plasmodium vivax-related malaria parasite: genetic variability of Duffy binding protein II and the Duffy antigen/receptor for chemokines |
| Q37775259 | Plasmodium vivax and the Duffy antigen: a paradigm revisited |
| Q42710505 | Plasmodium vivax circumsporozoite genotypes: a limited variation or new subspecies with major biological consequences? |
| Q33809115 | Plasmodium vivax tryptophan-rich antigen PvTRAg33.5 contains alpha helical structure and multidomain architecture |
| Q39381564 | Plasmodium vivax: comparison of immunogenicity among proteins expressed in the cell-free systems of Escherichia coli and wheat germ by suspension array assays |
| Q37018632 | Plasmodium vivax: who cares? |
| Q27021891 | Platform for Plasmodium vivax vaccine discovery and development |
| Q24273364 | Preclinical Assessment of Viral Vectored and Protein Vaccines Targeting the Duffy-Binding Protein Region II of Plasmodium Vivax |
| Q35649424 | Preserved dendritic cell HLA-DR expression and reduced regulatory T cell activation in asymptomatic Plasmodium falciparum and P. vivax infection |
| Q41808483 | RETRACTED: Fine specificity of Plasmodium vivax Duffy binding protein binding engagement of the Duffy antigen on human erythrocytes |
| Q30248811 | Recent insights into humoral immunity targeting Plasmodium falciparum and Plasmodium vivax malaria |
| Q28483318 | Reduced risk of Plasmodium vivax malaria in Papua New Guinean children with Southeast Asian ovalocytosis in two cohorts and a case-control study |
| Q36008345 | Strain-Transcending Inhibitory Antibodies against Homologous and Heterologous Strains of Duffy Binding Protein region II. |
| Q37333369 | Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean children |
| Q33959038 | Strategies for designing and monitoring malaria vaccines targeting diverse antigens |
| Q28544738 | Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine design |
| Q65937995 | Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody |
| Q92325722 | Structural basis for neutralization of Plasmodium vivax by naturally acquired human antibodies that target DBP |
| Q57157434 | Susceptibility to Plasmodium vivax malaria associated with DARC (Duffy antigen) polymorphisms is influenced by the time of exposure to malaria |
| Q37924616 | Synergism/complementarity of recombinant adenoviral vectors and other vaccination platforms during induction of protective immunity against malaria |
| Q47986739 | Targeting TLRs expands the antibody repertoire in response to a malaria vaccine |
| Q55669690 | Targeting a Reticulocyte Binding Protein and Duffy Binding Protein to Inhibit Reticulocyte Invasion by Plasmodium vivax. |
| Q27009149 | The Duffy binding protein as a key target for a Plasmodium vivax vaccine: lessons from the Brazilian Amazon |
| Q28396379 | The Presence, Persistence and Functional Properties of Plasmodium vivax Duffy Binding Protein II Antibodies Are Influenced by HLA Class II Allelic Variants |
| Q38945751 | The association of Duffy binding protein region II polymorphisms and its antigenicity in Plasmodium vivax isolates from Thailand |
| Q34606720 | The epitope of monoclonal antibodies blocking erythrocyte invasion by Plasmodium falciparum map to the dimerization and receptor glycan binding sites of EBA-175. |
| Q37471465 | The future for blood-stage vaccines against malaria |
| Q38666558 | The immunological balance between host and parasite in malaria |
| Q84511507 | The molecular genetics of blood group polymorphism |
| Q41707671 | The role of the human Duffy antigen receptor for chemokines in malaria susceptibility: current opinions and future treatment prospects |
| Q39026326 | The role of the red blood cell in host defence against falciparum malaria: an expanding repertoire of evolutionary alterations |
| Q39423371 | The upstream sequence segment of the C-terminal cysteine-rich domain is required for microneme trafficking of Plasmodium falciparum erythrocyte binding antigen 175 |
| Q33988630 | Worldwide Genetic Variability of the Duffy Binding Protein: Insights into Plasmodium vivax Vaccine Development |
Search more.